Our influential research and analysis attracts the attention of leading publishers every day.

Digital breast tomosynthesis (DBT) is due to revive the breast cancer imaging market in the developed world, installations expected to increase four fold in the US by 2016, and double in the EU.

Valeant Pharmaceuticals, Novartis and Mylan are circling Actavis, the world’s third largest generics manufacturer, for acquisition, but will anyone be able to afford the record-breaking price tag?

Takeda’s recently announced positive late-stage results for new type 2 diabetes drug, fasiglifam, has prompted excitement within the industry and raised hopes of reviving Takeda’s diabetes treatment business, following last year’s patent expiration of hit product Actos. But as drugs continue to imp

The expansion of the insured population, prompted by the introduction of Patient Protection and Affordable Care Act (PPACA), will play a key role in driving US pharmaceutical market revenue up by a third by the end of the decade.

High potential as a combination therapy and a better safety profile will see Arena’s new obesity drug Belviq surpass Vivus’ challenger Qsymia in the near-term battle to become the market’s dominant treatment, predicts an analyst with research and consulting firm GlobalData.

While the Australian LNG sector has massive financial potential, ballooning development costs, driven by the prodigious strength of the Australian dollar, are continuing to chip away at profit forecasts. But despite the emergence of such a challenging macroeconomic environment, the national governm

European Commission investigators raided the trading offices of three major oil companies and a price reporting agency this week amid complaints about price-fixing and collusion in the global crude oil, refined products and biofuels markets.

While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative vaccine, government-funded organizations and smaller biotech firms may provide the answer, a GlobalData analyst has said in a research note as World AIDS Vaccine Day approaches.

The introduction of new hepatitis C (HCV) drugs in the second half of 2013 will result in a significant increase in annual treatment costs and can lead to insurers slashing the number of patients eligible for coverage.

Italian pharmaceutical market value will continue to fall in the foreseeable future, due to government support of generics and a stringent drug pricing policy.